Status:
ENROLLING_BY_INVITATION
Long-term, High Blood Flow Hemoadsorption Therapy in Patients Undergoing Maintenance Hemodialysis
Lead Sponsor:
Dongliang Zhang, MD
Conditions:
Chronic Kidney Diseases
Hemodialysis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Objective：The purpose of the study is to confirm that extending the duration of hemoadsorption (HA) and increasing blood flow during the HA+hemodialysis (HD) treatment process is safe and feasible, an...
Eligibility Criteria
Inclusion
- Maintenance Hemodialysis Patients with Uremia receive regular HA+HD treatment
Exclusion
- Plasma albumin \<30g/L, severe malnutrition or cachectic state; platelet count \<40×10\^9/L or \>300×10\^9/L; hypercoagulable state allergy to the hemoperfusion device; new cardiovascular or cerebrovascular diseases; poor vascular access function, extracorporeal circulation blood flow unable to reach 250ml/min ultrafiltration volume \>4500ml in a single dialysis session use of non-heparin anticoagulants inability to comply with the procedures of this study other conditions deemed unsuitable for participation in this study by the investigator
- \-
Key Trial Info
Start Date :
August 28 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06574425
Start Date
August 28 2024
End Date
August 31 2025
Last Update
December 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nephrology Department of Beijing Jishuitan Hospital
Beijing, Beijing Municipality, China, 100035